# Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

> **NCT00069758** · PHASE2 · COMPLETED · sponsor: **Cephalon** · enrollment: 72 (—)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** SDX-105

## Key facts

- **NCT ID:** NCT00069758
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 72 (—)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00069758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00069758, "Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00069758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*